Filter Results
Clinical Studies
Results filtered:Study status:
Open
Contact Us for the Latest Status
Closed for Enrollment
Open
-
A Phase 1/2 Study Of EG-70 As An Intravesical Administration To Patients With BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) And High-Risk NMIBC Patients Who Are BCG Naïve Or Received Incomplete BCG Treatment
Scottsdale/Phoenix, Ariz.,
Rochester, Minn.
This study will evaluate the safety and efficacy of intravesical administration of EG-70 in the bladder and its effect on bladder tumors in patients with NMIBC.
This study study consists of two phases; a Phase 1 dose-escalation to establish safety and recommended the phase 2 dose, followed by a Phase 2 study to establish how effective the treatment is.
The Study will include patients with NMIBC with Cis for whom BCG therapy is unresponsive and patients with NMIBC with Cis who are BCG-naïve or inadequately treated.
-
A Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study To Evaluate The Safety And Efficacy Of Cretostimogene Grenadenorepvec In Participants With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
Jacksonville, Fla.,
Rochester, Minn.,
Scottsdale/Phoenix, Ariz.
A Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer
-
A Phase 2, Open-Label Study To Evaluate The Safety And Anti-Tumor Activity Of Intravesical Instillation Of TARA-002 In Adults With High-Grade Non-Muscle Invasive Bladder Cancer
Scottsdale/Phoenix, Ariz.,
Jacksonville, Fla.,
Rochester, Minn.
TARA-002-101-Ph2 is an open-label study to investigate the safety and anti-tumor activity of intravesical instillation of TARA-002 in adults 18 years of age or older with high-grade CIS NMIBC (± Ta/T1). The purpose of this Phase 2 study (TARA-002-101-Ph2) is to further assess the safety and anti-tumor activity of TARA-002 at the RP2D which has been established in the Phase 1a dose finding study (TARA-002-101-Ph1a). This Phase 2 study includes participants with CIS NMIBC (± Ta/T1) with active disease (defined as disease present at last tumor evaluation prior to signing ICF). Participants will be enrolled into one of 2 cohorts: Cohort A: -Participants with CIS (± Ta/T1) who are BCG naive, or -Participants with CIS (± Ta/T1) who are BCG exposed and have not received intravesical BCG for at least 24 months prior to the most recent CIS diagnosis Cohort B: -Participants with persistent or recurrent CIS (± Ta/T1) who are BCG unresponsive within 12 months of completion of adequate BCG therapy (minimum 5/6 doses induction and 2/3 doses maintenance or 2/6 doses reinduction)
-
A Phase 3b, Randomized, Controlled Trial Of Nadofaragene Firadenovec Vs. Observation In Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
Rochester, Minn.,
Scottsdale/Phoenix, Ariz.,
Jacksonville, Fla.
A phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants with Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC)
-
An Expanded Access Program Of Cretostimogene Grenadenorepvec In Patients With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive To Bacillus Calmette-Guerin (BCG)
Rochester, Minn.
This is an open-label, expanded access trial designed to provide access to cretostimogene in patients with NMIBC (specifically CIS with or without HG Ta/T1) unresponsive to BCG.
-
GAIN-BCG: Gemcitabine Alternating With INtravesical BCG Randomized Against BCG Alone For Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer
Scottsdale/Phoenix, Ariz.
This phase III trial compares the effect of adding gemcitabine to intravesical Bacillus Calmette Guerin (BCG) versus intravesical BCG alone in patients with non-muscle invasive bladder cancer that has come back after a period of improvement (recurrent). Gemcitabine is a chemotherapy drug that blocks the cells from making deoxyribonucleic acid (DNA) and may kill cancer cells. Intravesical BCG is a solution containing the live BCG bacteria that is placed in the bladder via a catheter (intravesical). When the solution comes into direct contact with the bladder wall, it stimulates the body's immune system which kills tumor cells. Giving gemcitabine with intravesical BCG may kill more tumor cells in patients with recurrent non-muscle invasive bladder cancer.
Contact Us for the Latest Status
Closed for Enrollment
-
A PhAse 1a/b, Dose Finding, Open-label Study To EValuate SAfety And Toxicity, Of INtravesiCal
instillation Of TARA-002 In Adults With High-gradE Non-muscle Invasive BlaDder Cancer
Jacksonville, Fla.,
Rochester, Minn.
The primary objective of this study is to characterize the safety and toxicity profile of TARA-002 administered intravesically.
-
A Phase 2, Open-Label, Multi-Center, Randomized Study Of TAR-200 In Combination With Cetrelimab And Cetrelimab Alone In Participants With Muscle-Invasive Urothelial Carcinoma Of The Bladder Who Are Scheduled For Radical Cystectomy And Are Ineligible For Or Refusing Platinum-Based Neoadjuvant Chemotherapy
Rochester, Minn.,
Jacksonville, Fla.
The purpose of this study is to evaluate the anti-tumor effects of TAR-200 in combination with cetrelimab and cetrelimab alone.
-
A Phase 2, Single Arm Study Of CG0070 Combined With Pembrolizumab In Patients With Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive To Bacillus Calmette-Guerin (BCG)
Rochester, Minn.
The primary purpose of this study is to evaluate the activity of intravesical administration of CG0070 and intravenous administration of Pembrolizumab in patients with tissue pathology-confirmed non-muscular invasive bladder cancer (NMIBC) who have Bacillus-Calmette-Guerin (BCG) unresponsive disease with carcinoma in situ (CIS) with or without Ta/T1 papillary disease.
-
A Phase 3 Study Of CG0070 In Patients With Non-Muscular Invasive Bladder Cancer (NMIBC) Unresponsive To Bacillus-Calmette-Guerin (BCG)
Scottsdale/Phoenix, Ariz.,
Jacksonville, Fla.,
Rochester, Minn.
The purpose of this study is to evaluate the activity of intravesical (IVE) administration of Cretostimogene Grenadenorepvec in patients with tissue pathology confirmed non-muscule invasive bladder cancer (NMIBC) who have Bacillus-Calmette-Guerin (BCG) unresponsive disease, with either carcinoma in situ with or without Ta/T1 disease.
-
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating The Efficacy And Safety Of TAR-200 In Combination With Cetrelimab Or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) In Participants With BCG-naïve High-Risk Non-Muscle Invasive Bladder Cancer
Scottsdale/Phoenix, Ariz.,
Rochester, Minn.
The purpose of this study is to compare event-free survival (EFS) in participants with Bacillus Calmette-Guerin (BCG)-naive high-risk non-muscle invasive bladder cancer (HR-NMIBC), including high-grade papillary Ta, any T1, or carcinoma in situ (CIS), between TAR-200 plus cetrelimab (Group A) and TAR-200 alone (Group C) versus intravesical BCG (Group B).
-
A Phase 3, Randomized Study Of Adjuvant Cretostimogene Grenadenorepvec Versus Observation For The Treatment Of Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC) Following Transurethral Resection Of Bladder Tumor (TURBT)
Jacksonville, Fla.,
Rochester, Minn.,
Scottsdale/Phoenix, Ariz.
This is a Phase 3, open-label, randomized trial designed to evaluate the RFS of TURBT followed by cretostimogene grenadenorepvec versus TURBT followed by surveillance for the treatment of participants with IR-NMIBC.
-
A Study Of Intravesical Bacillus Calmette-Guerin (BCG) In Combination With ALT-803 (N-803) In Patients With Non-Muscle Invasive Bladder Cancer
Jacksonville, Fla.,
Rochester, Minn.,
Scottsdale/Phoenix, Ariz.
For Cohort A, the purpose of this study is to determine the effectiveness of the combination of N-803 plus BCG compared to BCG alone in patients with CIS disease (with or without Ta/T1) in terms of complete response (CR) rate using cystoscopy, confirmatory bladder biopsy, and urine cytology. For Cohort B, the purpose is to determine the effectiveness of the combination of N-803 plus BCG compared to BCG alone in patients with high-grade papillary disease (Ta/T1 only) in terms of disease-free survival (DFS) using cystoscopy, confirmatory bladder biopsy, and urine cytology.
.